新型的微生物群Mesosutterella faecium sp. sp. 这种新型的微生物群 nov. 具有对炎症性肠病的保护作用
Seung Yeob Yu1,2, Byeong Seob Oh1, Seoung Woo Ryu1,2
1Korean Collection for Type Cultures, Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
Frontiers in microbiology
|April 18, 2024
概括
一种新型细菌Mesosutterella faecium从猪中分离出来,发现它产生低毒性脂多糖 (LPS). 这种菌株表现出抗炎性质,在动物模型中提供对炎症性肠病的保护作用.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 肠道微生物组在宿主免疫力和平衡中发挥着至关重要的作用.
- 某些细菌成分,如脂多糖 (LPS),可以调节免疫反应.
- 具有免疫调节性质的新型细菌菌株对治疗应用有兴趣.
研究的目的:
- 从猪便中分离和描述一种新的细菌菌株.
- 研究其脂聚糖 (LPS) 的特性及其免疫调节潜力.
- 在炎症性肠病 (IBD) 模型中评估新型菌株的抗炎作用.
主要方法:
- 隔离和16S rRNA基因测序用于细菌识别.
- 全基因组测序以分析遗传内容,包括LPS生物合成基因.
- 在体外巨细胞刺激测试以评估LPS毒性.
- 在小鼠中使用硫酸 (DSS) 诱导的大肠炎模型来评估抗炎活性.
主要成果:
- 一种新的格兰氏阴性,有约束性的无氧菌,AGMB02718T,被确定为一种新的Mesosutterella物种,命名为Mesosutterella faecium.
- 基因组分析显示,没有高毒性Kd2-Lipid A (KLA) 组合的基因,这表明LPS的低毒性生产.
- 实验室试验证实了低LPS毒性,体内研究表明对DSS诱导的大肠炎有保护作用.
结论:
- 梅索苏特雷拉菌 (Mesosutterella faecium AGMB02718T) 是一种新型细菌物种,具有独特的低毒性LPS.
- 这种菌株表现出显著的抗炎活性,表明其作为治疗炎症性肠病的益生菌的潜力.
- 这些发现突出了产生低毒性LPS的细菌的治疗潜力,用于维持宿主免疫恒温.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
173
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
173
01:30Inflammatory Bowel Disease II: Crohn's Disease
227
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
227
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161